A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy

Blood

Volumn 87, Issue 9, 1996, Pages 3607-3614

  Tepler, Isidore ^b   Elias, Laurence ^b   Smith II, John W ^b   Hussein, Mohamad ^b   Rosen, Gerald ^b   Chang, Alex Y C ^b   Moore, Joseph O ^b   Gordon, Michael S ^b   Kuca, Bernice ^b   Beach, Kathleen J ^b   Loewy, John W ^b   Garnick, Marc B ^b   Kaye, James A ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MITOXANTRONE; PACLITAXEL; PLACEBO; RECOMBINANT INTERLEUKIN 11; THIOTEPA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; LYMPHOMA; MALE; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYNCOPE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-11; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 9244234420     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wallace EL, Churchill WH, Surgenor DM, An J, Cho G, McGurk S, Murphy L: Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 35:802, 1995
2. Surgenor DM, Wallace EL, Hale SG, Gilpatrick MW: Changing patterns of blood transfusions in four sets of United States hospitals, 1980 to 1985. Transfusion 28:513, 1988
3. Sweeney J, Headon A: Medical Intelligence Unit: Clinical Benefits of Leukodepleted Blood Products. Austin, TX, R.G. Landes, 1995, p 185
4. Musashi M, Yang Y-C, Paul SR, Clark SC, Sudo T, Ogawa M: Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Nat Acad Sci USA 88:765, 1991
5. Musashi M, Clark SC, Sudo T, Urdal DL, Ogawa M: Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood 78:1448, 1991
6. Hirayama F, Shih J-P, Awgulewitsch A, Warr GW, Clark SC, Ogawa M: Clonal proliferation of murine lymphohemopoietic progenitors in culture. Proc Natl Acad Sci USA 89:5907, 1992
7. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H: Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 79:327, 1992
8. Bruno E, Briddell RA, Cooper RJ, Hoffman R: Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol 19:378, 1991
9. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire I, Schaub R, Goldman SJ: Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 81:901, 1993
10. Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Takatsuki K: Effect of recombinant human interleukin-11 on rat megakaryopoiesis and thrombopoiesis in vivo: Comparative study with interleukin-6. Br J Haematol 84:16, 1993
11. Witsell A, Mauch P, Neben TY, Quinto C, Leonard JP, Lamont C, Goldman SJ: Constant subcutaneous infusion of recombinant human interleukin-11 induces stem cell mobilization and causes prolonged elevation of peripheral platelets. J Cell Biochem Suppl 17B:71, 1993
12. Bree A, Schlerman F, Timony G, McCarthy K, Stoudemire J: Pharmacokinetics and thrombopoietic effects of recombinant human interleukin-11 (rhIL-11) in nonhuman primates and rodents. Blood 78:132a, 1991 (abstr, suppl 1)
13. Leonard JP, Quinto CM, Kozitza MK, Neben TY, Goldman SJ: Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 83:1499, 1994
14. Hangoc G, Yin T, Cooper S, Schendel P, Yang Y-C, Broxmeyer HE: In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood 81:965, 1993
15. Maze R, Moritz T, Williams DA: Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11. Cancer Res 54:4947, 1994
16. Du XX, Neben T, Goldman S, Williams DA: Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: Acceleration of recovery of peripheral blood neutrophils and platelets. Blood 81.27, 1993
17. Gordon MS, McCaskill-Stevens WJ, Battiato LA, Loewy J, Loesch D, Breeden E, Hoffman R, Beach KJ, Kuca B, Kaye J, Sledge GW: A phase 1 trial of recombinant human interleukin-11 (Neumega rhIL-11 Growth Factor) in women with breast cancer receiving chemotherapy. Blood 87:3615, 1996
18. Orazi A, Cooper RJ, Tong J, Gordon MS, Battiato L, Sledge GW, Kaye JA, Kahsai M, Hoffman R: Effects of recombinant human interleukin eleven (Neumega™ rhIL-11 Growth Factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol 1996 (in press)
19. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
20. SAS Institute Inc: SAS/STAT® Software: Changes and Enhancements (Release 6.07): SAS Technical Report P-229. Cary, NC, SAS Institute Inc, 1992
21. Ault KA, Mitchell J, Knowles C, Clendaniel A, Egan A, Loewy J, Garnick MB, Kaye JA: Recombinant human interleukin eleven (NEUMEGA™ rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects. Blood 84:276a, 1994 (abstr, suppl 1)
22. Demetri GD, Hayes DF, Merica EA, Cap B, Sparano J: Concurrent IL-6 + G-CSF to support dose-intensified cyclophosphamide/doxorubicin (CD): Possible acceleration of hematologic recovery from chemotherapy-induced thrombocytopenia. Blood 84:29a, 1994 (abstr, suppl 1)
23. Postmus PE, Gietema JA, Damsma O, Biesma B, Limburg PC, Vellenga E, de Vries EGE: Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: A dose-finding study. J Clin Oncol 10:1131, 1992
24. Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WN, Broxmeyer HE, Williams DE, Garrison L, Benjamin RS: Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/ interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 12:715, 1994
25. Smith JW II, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, Curti BD, Creekmore SP, Holmlund JT, Fenton RG, Sznol M, Miller LL, Shimizu M, Oppenheim JJ, Fiem SJ, Hursey JC, Powers GC, Urba WJ: The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med 328:756, 1993
26. Biesma B, Willemse PHB, Mulder NH, Sleijfer DT, Gietema JA, Mull R, Limburg PC, Bouma J, Vellenga E, de Vries EGE: Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80:1141, 1992
27. Demetri GD, Bukowski RM, Samuels B, Gordan M, Antman K, Merica EA, Samuel S, Campion M, Levitt D, Isaacs R: Stimulation of thrombopoiesis by recombinant human interleukin-6 (IL-6) pre- and post-chemotherapy in previously untreated sarcoma patients with normal hematopoiesis. Blood 82:367a, 1993 (abstr, suppl 1)
28. Crawford J, Figlin R, Chang A, Kamm J, Wasserheit C, Lee M, M. C, Manfreda S, Isaacs R: Phase I/II trial of recombinant human interleukin-6 (rhIL-6) and granulocyte colony stimulating factor (rhG-CSF) following ifosphamide, carboplatin and etoposide (ICE) chemotherapy in patients with advanced non-small cell lung carcinoma (NSCLC). Blood 82:367a, 1993 (abstr, suppl 1)
29. D'Hondt V, Weynants P, Humblet Y, Guillaume T, Canon J-L, Beauduin M, Duprez P, Longueville J, Mull R, Chatelain C, Symann M: Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 11:2063, 1993
30. Miller L, Smith J II, Urba W, Gause B, Janik J, Korn E, Garrison L, Holcenberg J, Longo D: A phase I study of an IL-3/ GM-CSF fusion protein (PIXY321) and high-dose carboplatin (CBDCA) in patients with advanced cancer. Proc Am Soc Clin Oncol 12:138, 1993
31. Runowicz CD, Mandeli J, Speyer J, Wadler S, Cohen C, Hochster H, Bruckner H, Goldberg G, Smith H, Garrison L, Wallach R, Tomaino C, Demakos E, Sorich J, Holland JF, NYGOG, Immunex: Phase I/II study of PIXY321 in combination with cyclophosphamide (CTX) and carboplatin (CP) in the treatment of patients (pts) with ovarian cancer (OC) Proc Am Soc Clin Oncol 12:260, 1993
32. Pisciotto PT, Benson K, Hume H, Glassman AB, Oberman H. Popovsky M, Hines D, Anderson K: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 35:498, 1995
33. Beutler E: Platelet transfusions: The 20,000 μL trigger. Blood 81:1411, 1993
34. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 338:1223, 1991
35. Goldberg GL, Gibbon DG, Smith HO, DeVictoria C, Runowicz CD, Burns ER: Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 12:2317, 1994